AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16262741 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (4 mg/kg daily for 3 days) plus Amodiaquine (30 mg/kg over 3 days)
Number of subjects: 153
Study 16262741 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg over 3 days) plus Pyrimethamine-Sulfadoxine (25 mg/kg of sulfadoxine at presentation)
Number of subjects: 153
Study 12122508 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD), started at least 7 days before transplantation (n=15)
Number of subjects: 31
Study 12122508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 31
Study 9802119 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive-behavioral and pharmacological therapy (fluoxetine for AN-R and AN-BP, amineptine for AN-BP and BN, fluvoxamine for BN)
Number of subjects: 26
Study 9802119 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age- and sex-matched controls)
Number of subjects: 26
Study 7697236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece breathing with noseclip
Number of subjects: 6
Study 7697236 — intervention group
Group type: COMPARATOR
Intervention: No mouthpiece and noseclip (control)
Number of subjects: 6
Study 2506671 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment (subcutaneously administered clinical grade heparin)
Number of subjects: 2
Study 2506671 — intervention group
Group type: COMPARATOR
Intervention: Nitrates and calcium-channel blockers without heparin
Number of subjects: 2
Study 742831 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 72
Study 742831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 72
Study 742831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analgesic-relaxant anaesthesia
Number of subjects: 72
Study 742831 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 72
Study 30203748 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride tablets
Number of subjects: 130
Study 30203748 — intervention group
Group type: COMPARATOR
Intervention: Cervical vertebra exercises and cervical occipital belt traction therapy (reference group)
Number of subjects: 130
Study 28918310 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 97
Study 28918310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 26461996 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical therapy (4 sessions)
Number of subjects: 220
Study 26461996 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no additional interventions)
Number of subjects: 220
Study 24107292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant (10 mg, 20 mg, or 40 mg a day)
Number of subjects: 95
Study 24107292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg, 200 mg, or 400 mg a day)
Number of subjects: 95
Study 24107292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 21396086 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tablet containing 1 mg vitamin B12
Number of subjects: 200
Study 21396086 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablet
Number of subjects: 200
Study 18285604 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 1000
Study 16516359 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 47
Study 16516359 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing
Number of subjects: 47
Study 14499225 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge strategy (pharmacological stress echocardiography on day 3-5)
Number of subjects: 458
Study 14499225 — intervention group
Group type: COMPARATOR
Intervention: Usual care strategy (clinical evaluation with hospital discharge on day 7-9 and symptom-limited post-discharge exercise electrocardiography)
Number of subjects: 458
Study 14499225 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge strategy
Number of subjects: 458
Study 14499225 — intervention group
Group type: COMPARATOR
Intervention: Usual care strategy
Number of subjects: 458
Study 11758131 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose nebulized albuterol (0.15 mg/kg)
Number of subjects: 29
Study 11758131 — intervention group
Group type: COMPARATOR
Intervention: Low dose nebulized albuterol (0.075 mg/kg) plus ipratropium-bromide (250 micrograms/dose)
Number of subjects: 29
Study 9390958 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (0.75 g/kg) + Pro (0.1 g/kg) + Fat (0.02 g/kg)
Number of subjects: 16
Study 9390958 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (1 g/kg)
Number of subjects: 16
Study 9390958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl; artificial sweetener)
Number of subjects: 16
Study 8426322 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of gentamicin and dexamethasone
Number of subjects: 61
Study 8426322 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shield soaked in gentamicin and dexamethasone
Number of subjects: 61
Study 8426322 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shield without drug
Number of subjects: 61
Study 3624680 — intervention group
Group type: EXPERIMENTAL
Intervention: mPEG-modified honeybee venom (200 micrograms maintenance dose)
Number of subjects: 35
Study 3624680 — intervention group
Group type: COMPARATOR
Intervention: unmodified honeybee venom (100 micrograms maintenance dose)
Number of subjects: 35
Study 3624680 — intervention group
Group type: EXPERIMENTAL
Intervention: mPEG-modified honeybee venom
Number of subjects: 35
Study 3624680 — intervention group
Group type: COMPARATOR
Intervention: unmodified honeybee venom
Number of subjects: 35
Study 1694913 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100-300 mg/day)
Number of subjects: 45
Study 1694913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5-15 mg/day)
Number of subjects: 45
Study 1694913 — intervention group
Group type: COMPARATOR
Intervention: Pindolol and Metoprolol
Number of subjects: 45
Study 4573205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment in epileptic patients
Number of subjects: 43
Study 4573205 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in epileptic patients
Number of subjects: 43
Study 4573205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment in normal subjects
Number of subjects: 43
Study 4573205 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in normal subjects
Number of subjects: 43
Study 31367742 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 1380
Study 31367742 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 1380
Study 28258505 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 120
Study 28258505 — intervention group
Group type: COMPARATOR
Intervention: Fact sheet
Number of subjects: 120
Study 26156739 — intervention group
Group type: EXPERIMENTAL
Intervention: rs16147 C allele
Number of subjects: 723
Study 26156739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 723
Study 26156739 — intervention group
Group type: EXPERIMENTAL
Intervention: rs16147 T allele
Number of subjects: 723
Study 22835079 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (80 mg)
Number of subjects: 0
Study 21076089 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission mammography (PEM)
Number of subjects: 388
Study 21076089 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance (MR) imaging
Number of subjects: 388
Study 21076089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PEM and MR imaging
Number of subjects: 388
Study 21076089 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM
Number of subjects: 388
Study 21076089 — intervention group
Group type: COMPARATOR
Intervention: MR imaging
Number of subjects: 388
Study 19259859 — intervention group
Group type: EXPERIMENTAL
Intervention: ASL cervical cancer education video
Number of subjects: 130
Study 19259859 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 130
Study 17277641 — intervention group
Group type: EXPERIMENTAL
Intervention: TrP palpation
Number of subjects: 20
Study 17277641 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous electromyographic activity
Number of subjects: 20
Study 12500005 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy in combination with Oral Rehydration Solution (ORS)
Number of subjects: 0
Study 12500005 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with Oral Rehydration Solution (ORS)
Number of subjects: 0
Study 10389785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 75 microg/kg IV
Number of subjects: 140
Study 10389785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 100 microg/kg IV
Number of subjects: 140
Study 8557897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 24 hours
Number of subjects: 28
Study 8557897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 72 hours
Number of subjects: 28
Study 8557897 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 0 hours (control group)
Number of subjects: 28
Study 1988573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, cytarabine, and dexamethasone (VADx)
Number of subjects: 256
Study 1988573 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin, cytarabine, and thioguanine (DAT)
Number of subjects: 256
Study 1988573 — intervention group
Group type: COMPARATOR
Intervention: Standard two‐cycle therapy
Number of subjects: 256
Study 1988573 — intervention group
Group type: COMPARATOR
Intervention: Four‐cycle regimen
Number of subjects: 256
Study 1988573 — intervention group
Group type: EXPERIMENTAL
Intervention: Best induction/continuation therapy combination
Number of subjects: 256
Study 1988573 — intervention group
Group type: EXPERIMENTAL
Intervention: Four‐cycle continuation therapy
Number of subjects: 256
Study 6409493 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetically based chemotherapy regimen before and after radiotherapy
Number of subjects: 86
Study 6409493 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 86
Study 31028124 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropalliative care
Number of subjects: 60
Study 31028124 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 28656073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) (>90% maximum heart rate)
Number of subjects: 27
Study 28656073 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) (70% maximum heart rate)
Number of subjects: 27
Study 25130281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 1126
Study 25130281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1126
Study 25130281 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg once daily
Number of subjects: 1126
Study 22476168 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation 4 g·d(‐1) for 1 week, then 6 g·d(‐1) for 4 weeks
Number of subjects: 21
Study 22476168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 21
Study 22104710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal citrate (0.3 M solution)
Number of subjects: 0
Study 22104710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal citrate with 2% lidocaine pretreatment
Number of subjects: 0
Study 22104710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal citrate mixed with 2% lidocaine
Number of subjects: 0
Study 22104710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IN saline)
Number of subjects: 0
Study 19323926 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid group (directly to catheterization laboratory)
Number of subjects: 546
Study 19323926 — intervention group
Group type: COMPARATOR
Intervention: Non-rapid group (admitted to CCU or cardiac ward first)
Number of subjects: 546
Study 19323926 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid group
Number of subjects: 546
Study 19323926 — intervention group
Group type: COMPARATOR
Intervention: Non-rapid group
Number of subjects: 546
Study 16782393 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 15462108 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg once daily)
Number of subjects: 30
Study 15462108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg once daily)
Number of subjects: 30
Study 10877199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 2 mg daily with sequential oral norethindrone acetate (NETA) 1 mg daily from days 12 to 22
Number of subjects: 42
Study 10877199 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol 0.05 mg daily with sequential oral NETA 1 mg daily from days 17 to 28
Number of subjects: 42
Study 9099116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 87
Study 9099116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural counselling (6 sessions)
Number of subjects: 87
Study 9099116 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural counselling (1 session)
Number of subjects: 87
Study 9099116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 1526057 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 59
Study 1526057 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 59
Study 3842217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 400
Study 3842217 — intervention group
Group type: COMPARATOR
Intervention: MLCu250
Number of subjects: 400
Study 30901496 — intervention group
Group type: EXPERIMENTAL
Intervention: Diploid genotypes under low-water availability treatment
Number of subjects: 2
Study 30901496 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexaploid genotypes under low-water availability treatment
Number of subjects: 2
Study 30901496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diploid and hexaploid genotypes under temperature and watering treatments
Number of subjects: 2
Study 30901496 — intervention group
Group type: COMPARATOR
Intervention: Water availability treatment
Number of subjects: 2
Study 30901496 — intervention group
Group type: COMPARATOR
Intervention: Temperature treatment
Number of subjects: 2
Study 29498786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal warm saline and pulmonary recruitment manoeuvre
Number of subjects: 200
Study 29498786 — intervention group
Group type: COMPARATOR
Intervention: Gentle abdominal pressure (Control)
Number of subjects: 200
Study 28361570 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐cm elastic cuff inflated to 160 mmHg
Number of subjects: 15
Study 28361570 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐cm nylon cuff inflated to 40% of arterial occlusion pressure
Number of subjects: 15
Study 25255696 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate home modifications (treatment group)
Number of subjects: 842
Study 25255696 — intervention group
Group type: COMPARATOR
Intervention: 3-year wait before modifications (control group)
Number of subjects: 842
Study 23178035 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐flutemetamol PET and MRI
Number of subjects: 72
Study 23178035 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐flutemetamol PET
Number of subjects: 72
Study 23178035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amyloid PET and MTA data
Number of subjects: 72
Study 21951559 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training program for 8 weeks
Number of subjects: 0
Study 21951559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports brace worn during all sports activities for 1 year
Number of subjects: 0
Study 21951559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neuromuscular training program for 8 weeks and sports brace worn during all sports activities for 1 year
Number of subjects: 0
Study 21951559 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study 18461499 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise consultation intervention
Number of subjects: 56
Study 18461499 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 16527696 — intervention group
Group type: EXPERIMENTAL
Intervention: BIRB 796 (10, 20, 30, or 60 mg twice daily for 8 weeks)
Number of subjects: 284
Study 16527696 — intervention group
Group type: EXPERIMENTAL
Intervention: BIRB 796
Number of subjects: 284
Study 16527696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 14553957 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g daily)
Number of subjects: 260
Study 14553957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 10880809 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 44
Study 9014958 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NMES/TENS
Number of subjects: 24
Study 9014958 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 24
Study 9014958 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 24
Study 9014958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8281733 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened length of initial hospital stay (9 +/- 3 days)
Number of subjects: 61
Study 8281733 — intervention group
Group type: COMPARATOR
Intervention: Long length of initial hospital stay (23 +/- 4 days)
Number of subjects: 61
Study 2871782 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day bevantolol
Number of subjects: 107
Study 2871782 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day bevantolol
Number of subjects: 107
Study 2871782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 107
Study 2871782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 30234576 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) combined with Standard Wound Care (SWC)
Number of subjects: 22
Study 30234576 — intervention group
Group type: COMPARATOR
Intervention: Standard Wound Care (SWC)
Number of subjects: 22
Study 27473173 — intervention group
Group type: EXPERIMENTAL
Intervention: PatientTIME intervention group
Number of subjects: 97
Study 27473173 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 25168526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser vaporization (980 nm)
Number of subjects: 115
Study 25168526 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 115
Study 23732754 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b, 250 μg, for at least 2 years
Number of subjects: 239
Study 21097433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib sodium (40 mg) at anesthesia induction (group A)
Number of subjects: 40
Study 21097433 — intervention group
Group type: COMPARATOR
Intervention: Intravenous parecoxib sodium (40 mg) 30 min before the completion of surgery (group B)
Number of subjects: 40
Study 21097433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17399824 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Heart Failure (DHF)
Number of subjects: 446
Study 17399824 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Heart Failure (SHF)
Number of subjects: 446
Study 17399824 — intervention group
Group type: COMPARATOR
Intervention: Comparison of DHF and SHF
Number of subjects: 446
Study 17399824 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors and aldosterone antagonists
Number of subjects: 446
Study 16377936 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 300
Study 16377936 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 300
Study 16377936 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 14567559 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta1b (8 million units every other day)
Number of subjects: 12
Study 14567559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11028492 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolytic therapy
Number of subjects: 250
Study 11028492 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thrombolysis
Number of subjects: 250
Study 11028492 — intervention group
Group type: COMPARATOR
Intervention: Conventional heparin/anticoagulation therapy
Number of subjects: 250
Study 11028492 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (both systemic and local)
Number of subjects: 250
Study 7647166 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline at 2.1 micrograms/kg (n = 4)
Number of subjects: 6
Study 7647166 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline at 4.2 micrograms/kg (n = 5)
Number of subjects: 6
Study 7647166 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 2566321 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (400 mg)
Number of subjects: 12
Study 2566321 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 12
Study 2566321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 324863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide gel (AG) 15 ml
Number of subjects: 44
Study 324863 — intervention group
Group type: COMPARATOR
Intervention: Dummy gel (DG)
Number of subjects: 44
Study 324863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide gel (AG)
Number of subjects: 44